Amgen Liabilities 2024

Amgen Liabilities

90.92 B USD

Amgen Dividend yield

Ticker

AMGN

ISIN

US0311621009

WKN

867900

In 2024, Amgen's total liabilities amounted to 90.92 B USD, a 47.94% difference from the 61.46 B USD total liabilities in the previous year.

Amgen Aktienanalyse

What does Amgen do?

Amgen Inc. is a global biotechnology company focused on the development and production of pharmaceuticals. It was founded in 1980 by William K. Bowes Jr. and George B. Rathmann in Thousand Oaks, California/USA. The founders had the vision to create new treatment options for serious diseases such as cancer, autoimmune diseases, and osteoporosis. Amgen faced difficulties in its early days due to limited financial resources and setbacks in research. However, the company succeeded in developing the first recombinant therapeutic protein drug, Erythropoietin (EPO), and bringing it to the market. Today, Amgen has become one of the largest biotechnology companies in the world with over 24,000 employees worldwide. The company is known for its research and development work in oncology, kidney diseases, blood disorders, inflammation, and bone diseases. Amgen's business model involves investing in research and development to develop new drugs and commercialize them in global markets. The company follows a "biological platform" strategy, focusing on biotechnology products based on proteins and antibodies. Amgen has several product lines, including Biologics, Biosimilars, and Small Molecules. Biologics are protein-based drugs manufactured using living cells. Biosimilars are products that have similar structures to existing biologics. Small Molecules are chemically manufactured drugs. Some of Amgen's most well-known products include Epogen and Aranesp (both Erythropoietin-releasing hormones), Neulasta and Neupogen (both granulocyte colony-stimulating factors), Enbrel (a TNF inhibitor for the treatment of rheumatoid arthritis), Prolia and Xgeva (both Denosumab inhibitors for the treatment of osteoporosis), and Blincyto (a bispecific antibody against cancer). Amgen is also involved in cancer immunotherapy and has a range of medications in its portfolio, including a CAR-T immunotherapy used for certain forms of acute lymphoblastic leukemia (ALL). In addition, Amgen specializes in the development of biosimilars. In 2017, the company introduced six biosimilars to the market, including copies of Enbrel and Humira for the treatment of rheumatoid arthritis. Biosimilars have the potential to reduce the costs of patient treatment as they are typically cheaper than the original products. Furthermore, Amgen works closely with other companies and research institutions to develop innovative products and technologies. The company has numerous partnerships and licensing agreements with other companies in the biotech industry to accelerate its growth and expand its product pipeline. Overall, Amgen has successfully established itself as one of the leading biotechnology companies in the world. It is known for its innovative products, investments in research and development, and partnerships with other companies. With its wide product portfolio and commitment to producing high-quality biological products, Amgen will continue to play an important role in the healthcare industry. Amgen ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Amgen revenue by segment

In the annual report of the Amgen share (US0311621009, 867900, AMGN), it breaks down its revenues into 2 segments: 1. Human Therapeutics, 2. Other. The Amgen stock (WKN: 867900, ISIN: US0311621009, Ticker Symbol: AMGN) is a leading investment for investors interested in participating in the Health Care sector.

Liabilities Details

Assessing Amgen's Liabilities

Amgen's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Amgen's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Amgen's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Amgen's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Amgen’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Amgen Stock

What is the level of liabilities of Amgen this year?

Amgen has a debt balance of 90.92 B USD this year.

What were the liabilities of Amgen compared to the previous year?

The liabilities of Amgen have increased by 47.94% increased compared to the previous year.

What are the consequences of high debt for investors of Amgen?

High liabilities can pose a risk for investors of Amgen, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Amgen?

Low liabilities mean that Amgen has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Amgen affect the company?

An increase in liabilities of Amgen can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Amgen affect the company?

A decrease in the liabilities of Amgen can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Amgen?

Some factors that can influence the liabilities of Amgen include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Amgen so important for investors?

The liabilities of Amgen are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Amgen take to modify the liabilities?

To change its liabilities, Amgen can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Amgen pay?

Over the past 12 months, Amgen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amgen is expected to pay a dividend of 14.1 USD.

What is the dividend yield of Amgen?

The current dividend yield of Amgen is .

When does Amgen pay dividends?

Amgen pays a quarterly dividend. This is distributed in the months of September, December, March, June.

How secure is the dividend of Amgen?

Amgen paid dividends every year for the past 19 years.

What is the dividend of Amgen?

For the upcoming 12 months, dividends amounting to 14.1 USD are expected. This corresponds to a dividend yield of 4.92 %.

In which sector is Amgen located?

Amgen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amgen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amgen from 6/7/2024 amounting to 2.25 USD, you needed to have the stock in your portfolio before the ex-date on 5/16/2024.

When did Amgen pay the last dividend?

The last dividend was paid out on 6/7/2024.

What was the dividend of Amgen in the year 2023?

In the year 2023, Amgen distributed 7.76 USD as dividends.

In which currency does Amgen pay out the dividend?

The dividends of Amgen are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Amgen stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Amgen

Our stock analysis for Amgen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amgen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.